
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Oncology in Veterinary Medicine
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1546047
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immune checkpoints are critical for the regulation of tumor growth and regression. Recently an effect of CD80 and CD86 on tumor regression in a benign canine cutaneous histiocytomahistiocytic neoplasm has been described. Further, the expression of MX dynamin like GTPase 1 (mx1) in cancer is linked to immune evasion. Thus, the present study aimed to investigate the effects of CD80 and CD86 in histiocytic sarcoma (HS), a rare and progressive malignancy in dogs and to elucidate the status of the Interferon-I pathway.Twenty-two tissue samples of HS from skin, lung and liver of 15 dogs were used.Immunohistochemistry targeting CD80, CD86, programmed death-ligand 1 (PD-L1), Survivin, cleaved Caspase-3 (Casp-3), STING and mx1 was performed. Slides were digitized and analyzed with QuPath.The numbers of CD86-and Casp-3 expressing cells showed a positive correlation. In the skin and lung, numbers of CD80 immunolabeled cells were higher than for CD86, while CD80 and CD86 levels were comparable in the liver. In general, low numbers of PD-L1 immunolabeled tumor cells were detected. Intranuclear Survivin expression was linked to Casp-3. Mx1 and STING were expressed in tumor cells.A possible link between CD86 and Casp-3 points to a role of CD86 in tumor cell death. The findings indicate relevant differences in CD80 and CD86 expression between organs and a function in histiocytic disease in dogs. Further, the expression of markers of the Interferontype-I pathway indicates a role in immune evasion.
Keywords: CD80, CD86, dog, Histiocytic Sarcoma, Immune checkpoint, MX1, survivin
Received: 16 Dec 2024; Accepted: 24 Mar 2025.
Copyright: © 2025 Diehl, Kirchhoff and Hansmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Florian Hansmann, Institute of Veterinary Pathology, Faculty of Veterinary Medicine, Leipzig University, Leipzig, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.